Navigation Links
Crux Biomedical Announces First Successful U.S. Implant of Its New Retrievable Inferior Vena Cava (IVC) Filter
Date:10/3/2007

ATLANTA, Oct. 3 /PRNewswire/ -- Crux Biomedical, Inc., a privately held medical device firm, announced that it has successfully completed the first implant in the United States of the Crux IVC Filter. The filter, used to prevent an often fatal pulmonary embolism (PE), was implanted at the Atlanta Medical Center by David Rosenthal, Chief of Vascular Surgery. Every year in the United States, approximately 600,000 patients develop a PE and between 120,000 - 150,000 die as a result. The revolutionary filter design provides unique self-centering, ease of retrieval and low profile.

"The Crux filter was extremely easy to deploy. We are excited with the devices' ability to routinely self center in the vena cava and as result, we anticipate improved retrievability," Rosenthal stated. Atlanta's David Rosenthal is the Principal Investigator for Crux's pivotal IDE study, which is being conducted at 12 leading medical institutions in the United States.

Retrievable IVC filters were first introduced in the United States in 2002. They offer physicians the option to leave the device in on a permanent basis or to remove the filter via minimally invasive methods, once the patient is through the period when they are at risk for a PE. However current retrievable filters offer challenges to physicians. "Tilting of an IVC filter makes subsequent retrieval very challenging and can take up to several hours to accomplish," said Frank Arko, co-founder of Crux and Chief of Endovascular Surgery at University of Texas Southwestern. "I was amazed how easy it was to retrieve the Crux filter in our initial implants outside the United States. We were able to deploy or remove the filter in less than 5 minutes."

Annual sales of IVC filter in the United States are estimated to be $252MM in 2008 and growing between 8-10% annually. Filters are increasingly being used as a result of increased diagnosis of deep vein thrombosis and the protection that they afford in cases of trauma
'/>"/>

SOURCE Crux Biomedical, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Biomedical engineering conference invites manufacturers
2. Manufacturing partnership will move into biotech and biomedical spaces
3. Biomedical Alliance about more than stem cells
4. Doyle seeks $2.5M for biomedical alliance
5. Students will show off biomedical devices to professors and investors
6. Biomedical alliance marks first full year
7. UW Biomedical Engineering awarded $2.9 million research grant
8. Having two biomedical tech centers in Wisconsin will help the state
9. New biomedical institute aims to unite business and academia in SE Wisconsin
10. Wisconsin publicly traded biomedical companies report gains this quarter
11. Speaker announces business members of IT Task Force

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...s been met for patients with advanced-stage, or... Nov. 24 /PRNewswire-FirstCall/ - AEterna Zentaris...a global biopharmaceutical company focused on endo...ve efficacy data from a Phase 2 study with its tar...rly AN-152), in patients with advanced or recurren...
(Date:11/24/2009)...wswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (... is scheduled to present at the Piper Jaffray 21st... at 11:30 a.m. Eastern Time (8:30 a.m. Pacific Tim...Jack Lief, Arena,s President and Chief Executive O... company, including its clinical development and d...
(Date:11/24/2009)...tomers with Partners Validated to Process and Anal... Ottawa, ON (PRWEB) Novemb...f products for biological sample collection, stabi...global partner program. The program offers signifi...ity and is designed to help partners scale and dif...
(Date:11/23/2009)...tive new study, a University of Utah scientist arg...r cause of global warming cannot be stabilized un...ds the equivalent of one new nuclear power plant e...e any substantial near-term departure from recentl... rates," says the new paper by Tim Garrett, an ass...
Breaking Biology Technology:AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 2Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 3DNA Genotek Launches Global Partner Program 2DNA Genotek Launches Global Partner Program 3Is global warming unstoppable? 2Is global warming unstoppable? 3Is global warming unstoppable? 4
...iences,(Nasdaq: MATK ) announced today the launch...s patented, vegetarian form of DHA omega-3 for bra...bread with vegetarian DHA,Oroweat 9 Grain Bread wi...ble at major retailers in the Pacific Northwest, C...from Bimbo Bakeries demonstrates the broad range o...
...ernational Inc. (NYSE: BAX ) announced today that...e of an additional $2 billion of the company,s,com...mpany,s existing share,repurchase authorization., ...thorization under its,previous $2 billion share re.... Shares will be repurchased in the open market at...
...es Therapeutics,Inc. (Nasdaq: TPTX ) today announ... muscarinic agonist in development for xerostomia,...he company is conducting a randomized, double-blin...n square design to evaluate,the safety, tolerabili...ximately 24 patients will be enrolled at three sit...
Other Biology Technology:Martek Announces Launch of Oroweat 9 Grain Bread, First Bread with Martek's life'sDHA 2Martek Announces Launch of Oroweat 9 Grain Bread, First Bread with Martek's life'sDHA 3Baxter's Board of Directors Approves New Share Repurchase Authorization of $2 Billion 2TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 2TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 3TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 4
(Date:11/24/2009)...s to understanding how sounds associated with Navy... or if they hear it at all. , The same type of ...es to detect flaws in the space shuttle,s behemoth...peek inside the giant head of a whale. The scans a...f a whale,s hearing anatomy using a breakthrough m...
(Date:11/24/2009)...kable class of ring-shaped protein motors has been...ey National Laboratory (Berkeley Lab) using a stat...he Advanced Light Source (ALS). These protein moto...cation, and are vital to the survival of all biolo... the human papillomavirus, which has been linked t...
(Date:11/24/2009)... held secrets of the earth,s history locked in its...ry little information on the environments that hav... years. Now, a team of researchers from nine insti...ne of $10 million dollars by the National Science ... literally. These scientists will drill through t...
Breaking Biology News(10 mins):Rocket science leads to new whale discovery 2Atomic-level snapshot catches protein motor in action 2Atomic-level snapshot catches protein motor in action 3Atomic-level snapshot catches protein motor in action 4LSU gets to the bottom of things -- in Antarctica 2Researchers begin to decipher metabolism of sexual assault drug 10831 1Researchers begin to decipher metabolism of sexual assault drug 10831 2Leahy Will Vote to End Health Bill Filibuster Plans to Offer Amendment to End Health Insurers Antitrust Exemption 61782 1Warner Chilcott Prices Secondary Equity Offering 6425 1Warner Chilcott Prices Secondary Equity Offering 6425 2Warner Chilcott Prices Secondary Equity Offering 6425 3Warner Chilcott Prices Secondary Equity Offering 6425 4
...can Society for Microbiology (ASM) Siemens Healthc...presented to Adrian M. Zelazny, Staff Scientist, L...National Institutes of Health (NIH). This award re...microbiology or antimicrobial therapy. , Dr. Zela...ceptibility and resistance, microbial virulence, a...
...ion of biosolids (treated municipal sewage sludge)... source of plant nutrients and organic matter. How... in biosolids led to concerns that farmland applic...l and their subsequent translocation through the h...ns have extremely high bioaccumulation potential. ...
...c and professional organization of more than 16,00...lications, technology and science of molecular ima...esearch grants to support molecular imaging resear...esearch Foundation, represent the society,s commit... supporting the next generation of researchers. ,...
Other Biology News:Dioxin risk in soil and plant tissues after long-term biosolids application 2SNM awards $300,000 to support molecular imaging research 2
...0 (CYP450) metabolite postulated to play an autaco...rat cerebral microvessels, 20-HETE is a vasoconstr...y vasoconstriction. 20-HETE is excreted mainly as ...ee 20-HETE (20-40 pg/ml in human urine) is about 1...
...m enables you to insert a transposable element of ... transposition. It uses TnsABC* Transposase to ins... target. Target DNA may be a plasmid, cosmid, BAC ...nterests (6-8). If the insertion site is within a ...
Peptide Standards from New England Biolabs
CORNING CELLSTACK VENTED CAP, 33MM, STERILE, 0.2UM MEMBRANE from Sigma-Aldrich
Biology Products: